


September 4-7 2018, Boston, MA

CAR-TCR Summit



Moments where we can come together with passionate individuals and companies who are focused on advancing cancer care are inspiring, and the CAR-TCR Summit is no different...

Novartis

Changing Lives with CAR-T & TCR Cell Immunotherapies

700+ Attendees

300+ Organisations

90+ Expert Speakers

1 Comprehensive CAR-TCR Showcase

Expert speakers include:



Carl June
Professor & Director
Translational
Research, Abramson
Cancer Center
**University of
Pennsylvania**



David Chang
CEO
**Allogene
Therapeutics**



Usman Azam
President & CEO
Tmunity



André Choulika
CEO
Collectis



James Noble
CEO
Adaptimmune



Philip Gregory
CSO
bluebird bio

Lead Partner



Miltenyi Biotec

Expertise Partner



TERUMOBCT
Unlocking the Potential of Blood

Tel: +1 212 537 5898

Email: info@hansonwade.com www.car-tcr-summit.com



@CAR_TCell



Cell Immunotherapy

PRODUCED BY



Welcome to the 4th Annual CAR-TCR Summit

The comprehensive summit dedicated to accelerating the development of the next generation, potent and effective CAR-TCR therapies for solid tumor indications, ensuring accessibility and commercial delivery of current and novel cell immunotherapies to patients around the world.

With two CD19 approved drugs and both going head to head in DLBCL, the space is getting increasingly crowded - that is why at the **CAR-TCR Summit** you will **leverage the experience from those leaders first to market**, whilst unveiling the next generation technologies and breakthroughs being developed to enhance CAR-TCR efficacy, particularly in solid tumor indications.

The **CAR-TCR Summit** will **guide you through the full end-to-end development process** from basic research through to patient delivery.

The industry's experts will gather to discuss:

- Novel precision genetic engineering to improve solid tumor targeting
- Mechanisms to overcome the tumor microenvironment
- Clinical development to identify biomarkers of response

- Automation and manufacturing processes to reduce the overall cost of goods and improve turn around time
- Streamlined logistics of vein to vein delivery
- Regulations and reimbursement to ensure accessibility and global commercial delivery

Bringing you exclusive insight and unrivaled networking opportunities so you can **stay at the very forefront of this rapidly progressing field**, the **CAR-TCR Summit** is your one stop shop for all your engineered cell immunotherapy needs.

Network, interact and learn at the premier end-to-end meeting that **fosters the transformation of leading immuno-oncology** science into safe, effective and commercially successful cell therapies

■ The CAR-TCR team are passionate about moving the cell immunotherapy space forward to find a cure for cancer. That's why we work extremely hard to create a platform for experts to learn, network and find solutions to their shared challenges. The end goal is to ensure you can bring safe, effective and commercially viable CAR-T and TCR therapies to patients in need. Because regardless of whom you work for or where you've come from, every single person in this industry no matter how far removed, ultimately has one goal. Changing lives with CAR-T and TCR therapies ■■

Shaksita Desai, Brand Director, CAR-TCR Series, Hanson Wade

Contents

▶ What's New & Highlights	3
▶ Why Attend	4
▶ Expert Speakers	5
▶ Agenda at a Glance	8
▶ Which track	9
▶ Deep Dive Discussion Day	10
▶ Summit Day 1	12
▶ Summit Day 2	15
▶ Focus Day	17
▶ Build Your Own Experience	20
▶ Partnering with CAR-TCR Summit	21
▶ Partners	22
▶ Pricing & Venue	24

What's New in 2018?

Next Generation Leader's Fireside Chat



This exclusive Executive Next Generation CAR-TCR Therapies Fireside Chat is your chance to get unrivaled access to the leaders that are challenging traditional approaches and gain unprecedented insights to their innovative strategies, pipeline and development moves as the pioneers in this industry look to revolutionize and energize the development of CAR-TCR therapies.

15 Deep Dive Sessions



With so much content and data to share across the meeting, there can be often limited time to really get into the meat of a topic. With 15 hand-picked deep dive sessions we give you the opportunity to learn from leaders in key topic areas. These sessions provide an enhanced learning experience and are a more intimate opportunity to not only learn from experts but also to interact with the audience in a frank, open and peer level conversation. And if you miss a session, join the 1 hour debriefs to get the low down on all the sessions from the leaders themselves.

Focus Day Agendas



You and the industry identified two key areas of opportunity and great interest in the field – CAR-T strategies for solid tumors and alternative CAR strategies. Join us for a full day agenda dedicated to each of these two topics discussing everything from early innovations through to manufacturing and commercialization.

5 Dedicated Tracks



"An end-to-end industry focused summit" that's the label on this event's tin. And this year with even more content than ever, we bring you 5 streams dedicated to each of the key development milestones:

1. **Discovery:** Novel innovations in improving CAR-TCR therapies for solid tumor indications utilizing non-viral gene engineering and allogeneic approaches
2. **Translation:** Improve the clinical development of CAR-TCR therapies with biomarkers to enhance clinical trial design
3. **Manufacturing:** Ensure robust, scaled and quality manufacturing and reduce CoGs with breakthrough automation technologies
4. **Logistics:** Create an extensive and reliable infrastructure for vein to vein CAR-TCR transport, logistics and delivery
5. **Commercialization:** Explore the commercial landscape and what is required to ensure you can create affordable CAR-TCR Therapies in the brand new commercialization stream

Late Breaking Abstracts



At the leading comprehensive platform for CAR-T and TCR therapy leaders, we bring you the very latest clinical data from 3 key CAR-T therapy programs, releasing unpublished data for the first time. Join this session to hear these clinical read outs in real time before they hit the headlines!

Tech Slam @ The Innovation Hub



This field, more than any other, needs all stakeholders from the industry to play their part in the innovation of technologies to improve, support or revolutionize current processes. Take part as these key stakeholders give you a demonstration and the low down on these innovations and how you can integrate them into your strategies.

Why You Should Attend the CAR-TCR Summit

Well organized conference that brought the leading researchers and sponsors together to discuss topics highly relevant to the field. Well done.



This meeting enables us to know what is happening and what to care in the real world. It is extremely informative to consider what to do when we apply CAR or TCR to patients in Japan.



A nice blend of academic, biotech, and pharmaceutical attendance in an environment that encourages cross-fertilization of ideas within CAR-T therapy.



I can't speak highly enough about this conference. This conference allowed me to keep informed of the latest research and development on T cell therapies. I was also able to network with some of the leaders in T cell immunotherapies from both academia and the industry.



Memorial Sloan Kettering
Cancer Center

As a newcomer to the CAR-T space, I felt this meeting to be extremely valuable as it provided me the opportunity to meet many of the movers and shakers in the space. Great education and information!



This meeting was very informative and focused on cell therapies. You're able to learn a lot from the presentations whilst meet leaders of the field. We have already confirmed sponsorship for next year.



Where science, translation, clinical trial, and commercialization of new therapies meet.



Great opportunity to interact with both academic and industry leaders in the field of CAR T cell therapy.



The technology showcase was excellent. Being able to engage new vendors and see new devices and technology was outstanding. As always, the scientific program was exceptional - very high calibre, very well organized. Very well done! Another outstanding conference. Thank you for everything.



Keynote Experts



James Noble
CEO
Adaptimmune



David Chang
CEO
Allogene Therapeutics



Philip Gregory
CSO
bluebird bio



Jennifer Fillman
VP & GM,
Specialty Services
Cardinal Health Specialty Solutions



André Chouluka
CEO
Collectis



Philip Vanek
GM, Cell Therapy
Growth Strategy
GE Healthcare



Usman Azam
President &
CEO
Tmunity



Carl June
Professor & Director
Translational
Research, Abramson
Cancer Center
University of Pennsylvania

Deep Dive Discussion Day Expert Speaker Faculty:



Rick Morgan
Vice President of
Immunotherapy
bluebird bio



David Sourdiv
EVP,
Technical
Operations
Collectis



Chris Leamon
Vice President
of Research
Endocyte



Ali Mohamed
VP, CMC
Immatics



Eileen Higham
Head of Analytical
and Process
Development
Juno Therapeutics



Edmund Pezalla
CEO & Founder
Enlightenment Bioconsult LLC



Steven Feldman
Director, Surgery
Branch Vector
Production
Facility
National Cancer Institute (NCI) in NIH



Therese Choquette
Analytical Project
Leader, Cell and
Gene Therapy
Development and
Manufacturing
Novartis



Rodney Rietze
Enabling
Technology
and Strategic
Development
Novartis



Simon Lacey
Director
Translational
and Correlative
Studies Laboratory,
Center for Cellular
Immunotherapies,
University of Pennsylvania



Avery Posey
Instructor,
Department
of Pathology
& Laboratory
Medicine
University of Pennsylvania



Bruce Levine
Founding
Director of the
Clinical Cell
and Vaccine
Production
Facility (CVPF)
University of Pennsylvania



Roderick O'Connor
Instructor, Center
for Cellular
Immunotherapies
University of Pennsylvania School of Medicine

Summit Days Expert Speaker Faculty:



Yama Abassi
VP, Global
Strategic
Business
Development
ACEA Biosciences



Eric Von Hofe
President
Affymune Therapeutics



Claudia Zylberberg
CEO
Akron Biotech



Barbra Sasu
CSO
Allogene Therapeutics



Yajin Ni
Director, CART
Manufacturing
Process
Development
Allogene Therapeutics



Boro Dropulic
CSO & General
Manager,
Lentigen
Technology
a Miltenyi Biotec Company



Chris Haqq
EVP, R&D &
CSO,
Atara



Jim Faulkner
SVP & Head of
Product Delivery
Autolus



Jamie Margolis
Director, Product
Development
Operation
**Be The Match
BioTherapies**



David Spencer
CTO
**Bellicum
Therapeutics**



Gillian Payne
Director, Vector
Analytics
bluebird bio



**Peter
Olagunju**
VP
bluebird bio



Andy Philips
CEO
**C4
Therapeutics**



Jie Jia
VP
**CARsgen
Therapeutics**



George O'Sullivan
Executive Director,
Global CAR-T
Supply Chain
Celgene



Mike Stella
Chief Business
Officer and Director
**Cognate
Bioservices**



**Mark
Sawicki**
Chief
Commercial
Officer
Cryoport



Cheng Liu
CEO
**Eureka
Therapeutics**



Bob Valamehr
VP, Cancer
Immunotherapy
**Fate
Therapeutics**



Richard Grant
Chief Product
Officer
**FloDesign
Sonics**



Axel Hoos
SVP, TA, Head
Oncology R&D
GSK



Robert Preti
CEO & President
**Hitachi Chemical
Advanced
Therapeutics
Solutions**



Lei Xiao
CSO
**Innovative
Cellular
Therapeutics**



Steffen Walter
Co-Founder &
CSO
Immatics



Andrew Brown Jr
Director, Diversity
and Equity
Advocacy
**International
Cancer Advocacy
Network**



Jessie Ni
Chief Scientific
Officer
Irvine Scientific



Sean MacKay
CEO
Isoplexis



John Rossi
Director, Translational
Sciences
**Kite Pharma, a Gilead
Company**



Peter Emtage
Global Head of
Cell Therapy
**Kite Pharma,
a Gilead
Company**



Yuan Xu
CEO
Legend Biotech



Bala Manian
Executive
Chairman
LeukoDx



Nina Bauer
Commercial
Development
Lead,
Autologous
Cell Therapy
Lonza



**James
Kochenderfer**
Investigator,
Experimental
Transplantation &
Immunology Branch
**National Cancer
Institute**



**Saad
Kenderian**
Director, T cell
Engineering
Program
Mayo Clinic



**Dolores
Schendel**
CEO & CSO
Medigene



Rona Singer Weinberg
Director, Cellular
Therapy Laboratory
Director, MPD
Laboratory
**New York Blood
Center, Blood Centers
of America**



Koji Tamada
CSMO
**Noile-
Immune
Biotech**



Matthew Robson
Global Head Medical
Affairs, Cell & Gene
Therapies Unit
Novartis



**Samuele
Butera**
Global Cell &
Gene Therapies
Business
Leader
Novartis



**Devon
Shedlock**
VP, Preclinical
Development
**Poseida
Therapeutics**



**Vita
Golubovskaya**
Director R&D,
BD
**Promab
Biotechnologies**



Scott Ohanesian
Senior VP of Commercial
Operations, Clinical Trial
Logistics
**QuickSTAT, a Quick
Company**



Bing Wang
CEO
**Refuge
Biotechnologies**



Jeffrey Tice
Professor of
Medicine, Division
of General Internal
Medicine, University
of California
San Francisco



Gary Lee
Vice President,
Cell Therapy
**Sangamo
Biosciences**



Rob Jones
Global Director,
Advanced
Therapy
**Thermo Fisher
Scientific**



Jon Ellis
Senior Director,
Technical
Services
ThermoGenesis



**Joseph
McGuirk**
Professor of
Medicine
**The University of
Kansas**



Heidi Hagen
Co-founder &
CSO
Vineti

Focus Day Expert Speaker Faculty:



Mark Dudley
Senior Vice
President of
Bioprocessing
Adaptimmune



Paul Rennert
President & CSO
Aleta
Biotherapeutics



Steven Kelly
President and
CEO
CARMA
Therapeutics



Zonghai Li
Founder, CEO
and CSO
CARSgen
Therapeutics



**Stefanos
Theoharis**
SVP,
Partnering
and Corporate
Development
Cell Medica




Benham Badie
Professor
& Chief,
Division of
Neurosurgery
& Director
City of Hope
Medical Center



Bijan Nejadnik
CMO
Eureka
Therapeutics



Jim Beitel
SVP, Corporate
Development
Fate Therapeutics



Cameron Durrant
Chairman and
Chief Executive
Officer
Humanigen, Inc.



Isabelle Riviere
Director, Cell
Therapy and Cell
Engineering Facility
Memorial
Sloan Kettering
Cancer Center



Sadik Kassim
Chief Scientific
Officer
Mustang Bio



**Mario
Marcondes**
Medical
Director,
Clinical
Development
Nektar
Therapeutics



Michael Leek
Chief Executive
Officer
TC Biopharm



**Robert
Hofmeister**
CSO
TCR2
Therapeutics



John Connolly
Chief Scientific
Officer
Tessa
Therapeutics



Charles Sentman
Director, Center for
Synthetic Immunity
Professor,
Department of
Microbiology &
Immunology
The Geisel School
of Medicine at
Dartmouth



Thomas Andresen
Co-founder and
CSO
Torque
Therapeutics



David Porter
Director of Cell
Therapy and
Transplant
University of
Pennsylvania



Miguel Forte
Chief Executive
Officer
Zelluna
Immunotherapy

Where science, translation, clinical trial, and commercialization of new therapies meet.

Past Attendee, Director of Pfizer



Agenda at a Glance

Deep Dive Discussion Day Tuesday September 4th 2018	Summit Day 1 Wednesday September 5th 2018	Summit Day 2 Thursday September 6th 2018	Focus Day Friday September 7th 2018	
Workshops A, B, C, D, E	Plenary Presentations	Plenary Presentations	Plenary Presentations: Agenda 1	Plenary Presentations: Agenda 2
Morning Workshop Debrief	Speed Networking	Networking	Morning Refreshments	
Workshops F,G, H, I, J	Stream A Stream B Stream C Stream D Stream E	Stream A Stream B Stream C Stream D Stream E	Plenary Presentations: Agenda 1	Plenary Presentations: Agenda 2
Lunch Workshop Debrief	Lunch	Lunch	Lunch	
Workshops K,L,M,N,O	Stream A Stream B Stream C Stream D Stream E	Stream A Stream B Stream C Stream D Stream E	Plenary Presentations: Agenda 1	Plenary Presentations: Agenda 2
Afternoon Workshop Debrief	Poster Session	Refreshments	Afternoon Refreshments	
Evening Reception Hosted by Draper Laboratories Attendance by Invitation Only	Stream A Stream B Stream C Stream D Stream E	Stream A Stream B Stream C Stream D Stream E	Plenary Presentations: Agenda 1	Plenary Presentations: Agenda 2
Close of Discussion Day	Drinks Reception	Close of Summit	Close of Focus Day	

Which Track is Best for You?

CAR-TCR Discovery Track:

If you are interested in accessing the very latest advancements in basic research, discovery and preclinical validation of future CARs, then this is the track for you.

Join us to discuss:

- Challenge of finding unique antigens
- Survival and durability of CAR-T cells in vivo
- Tumor microenvironment and infiltration of CAR-T cells in solid tumors
- Off target effects of therapy
- Cytokine Release Syndrome and neurotoxicity challenges
- Safety switches and their mechanisms to improve efficacy
- Non viral gene editing approaches such as CRISPR or TALEN

CAR-TCR Translation Track:

Not just clinical data but also the translational work happening around clinical trials, such as biomarkers and combination therapies.

Join us to discuss:

- The latest clinical case studies in the industry
- Clinical trial design and management
- Optimizing pre-conditioning regimes for improved therapy efficacy
- Patient selection and recruitment
- Biomarkers of response
- Immunoassays to measure the immunogenicity of therapies
- Long term follow up and correlative studies

CAR-TCR Manufacturing Track:

Just as it says on the tin – this track is focused on all things manufacturing, from starting material and apheresis through to automation innovations.

Join us to discuss:

- Cell processing and characterization
- Release criteria and potency testing
- Reducing the CoGs through automation
- Effective Scale up of manufacturing
- Overcoming the viral vector bottleneck
- Quality assurance and ensuring flawless transactions every time
- Robust and reliable delivery every time

CAR-TCR Transport, Logistics & Supply Chain Track:

Brand new for this year, this track is dedicated to streamlining your logistics to ensure effective and efficient vein to vein delivery.

Join us to discuss:

- Effective patient scheduling to ensure streamlined care delivery
- Product customization to ensure the appropriate logistics
- Logistics modifications for allogeneic therapy delivery
- Efficient global delivery of CAR-TCR therapeutics
- Creating and building the appropriate infrastructure for delivery
- Cryopreservation and storage of CAR-TCR therapies
- Simplifying CAR-TCR cold chain supplies

CAR-TCR Commercialization Track

Focused on ensuring the product you get to market is the best it possibly can be whilst learning from those that have already been in the trenches.

Join us to discuss:

- Regulations for approval: what are the requirements
- Pricing models and case studies
- Reimbursement and payer perspectives
- Market access and health economics
- Patient advocacy and ensuring the patient comes first
- Ethical considerations for pricing curative therapies
- Post market analysis of therapies

Deep Dive Discussion Day | Tuesday September 4th

CAR-TCR Discovery Track

9.00 – 11.00am Optimizing Fuel Selection for CAR-T Cell Metabolism

- Presenting findings showing that glutamine metabolism is enhanced in CD28 δ CAR-T cells redirected against the solid tumor antigen mesothelin. These findings provide mechanistic insight into central metabolic pathways supporting clonal expansion and differentiation in disparate tumor environments
- Metabolically reprogramming CAR-T cells to give them a competitive advantage in the TME
- Remodeling the TME to enhance cell-based adoptive immunotherapy
- Integrating metabolic assays and models to enhance our understanding of CAR-T cell metabolism and function in the TME

Roderick O' Connor, Instructor, Center for Cellular Immunotherapies, **University of Pennsylvania School of Medicine**

CAR-TCR Translation Track

9.00 – 11.00am How Will Gene Editing Take Off-The-Shelf Allogeneic Cell Therapies to the Next Stage in the Future?

- What qualities make up a good donor to avoid rejection
- Genetic engineering strategies to reduce recognition as a foreign body
- Data from clinical trials to address current allogeneic status

David Sourdive, Executive Vice President Technical Operations, **Cellartis**

CAR-TCR Manufacturing Track

9.00 – 11.00am Vector Production Challenges for Multi-Product Cell Therapy Programs

A discussion of vector production platforms:

- Vector production for a multi-product cell therapy program
- Challenges associated with targeting shared versus patient-specific antigens
- Strategies to streamline vector production and biosafety testing

Steven Feldman, Director, Surgery Branch Vector Production Facility, **National Cancer Institute (NCI) in NIH**

CAR-TCR Transport, Logistics & Supply Chain Track

9.00 – 11.00am Manufacturing and Supply Chain Strategies for Engineered T Cell Therapies

- Modeling of autologous and allogeneic T cell production and the effect on COGs of US or offshore production
- A simulation approach for production facility and supply chain design for cell therapeutics: A regional or national network of such facilities and product distribution to point of care
- "What if" scenarios can be proposed to interrogate the effect on system-wide cost, and fulfillment time and variability

Bruce Levine, Founding Director of the Clinical Cell and Vaccine Production Facility (CVPF), **University of Pennsylvania**

CAR-TCR Commercialization Track

9.00 – 11.00am IP and Licensing: Navigating the Landscape

- Discuss the evolution of this field from the first generation patents to the current state of the field
- Get insight into practical strategies for transforming their discoveries and new constructs into IP, and the types of short term and long term IP issues that will confront them
- A case study of a hypothetical CAR-T construct
- Licensing-related aspects of CAR-T IP from a practical perspective
- How to interact with business people and their attorneys

Shawn Foley, Attorney, Intellectual Property, **Burns & Levinson**

11.00 – 12.00pm **Lunch & Debrief**

Deep Dive Discussion Day | Tuesday September 4th

12.00 – 2.00pm Bi-specific Adaptor Controlled CAR-T Cell Therapy for Solid and Liquid Tumors

- CAR-T adaptor molecule (CAM)-based therapy will be discussed. A review of the application of EC17 (folate-FITC) which effectively “paints” folate receptor-positive tumors with the FITC antigen which attracts anti-FITC CAR-T cells to induce an immune response
- Methods to mitigate or prevent severe cytokine release syndrome (sCRS). Strategies include i) the use of intermittent “on-and-off” dosing and/or dose titration of the EC17 CAM, and ii) application of intravenous rescue agents (e.g. sodium fluorescein) for rapid displacement of CAR-T cells from their targets to reverse the sCRS symptoms without apparent compromise to efficacy
- A description of the first human trial for osteosarcoma (to start in 4Q18) will be presented

Chris Leamon, Vice President of Research, **Endocyte**

12.00 – 2.00pm Optimizing the Predictive Value of Preclinical Models for Translation of Adoptive Immunotherapies into Human Trials

- Explore the most appropriate models to evaluate CAR-T treatment and limitations
- Outline current understandings in clinical evaluation of CAR-T cells and evaluate whether current preclinical models can predict CAR-T therapy safety and efficacy
- Identify animal models that present the best representation of the tumor microenvironment

Avery Posey, Instructor-level Faculty, **University of Pennsylvania**

12.00 – 2.00pm Specifications for Release Criteria

- Approaches used to set specifications for release of CGT product
- Challenges in setting criteria for autologous cell therapy product
- Revision of set specifications for release

Therese Choquette, Analytical Project Leader, Cell and Gene Therapy Development and Manufacturing, **Novartis**

12.00 – 2.00pm Manufacturing Of Tcr Based T Cells For Solid Tumors: Experience And Lessons Learned

- Manufacturing challenges using variable starting material
- Open vs closed systems
- Critical raw material including viral vectors
- Assay development
- Stability testing for T cell products and lentiviral vectors

Ali Mohamed, Vice President, CMC, **Immatics US Inc.**

12.00 – 2.00pm Innovation in Reimbursement for Cellular Therapies: a US Perspective

- Explore value frameworks and cost effectiveness of CAR-T therapies
- Implications and application: the ICER Value Framework
- Payers are concerned; explore patient turnover with new data and adverse selection
- Identify alternative payment models and discuss solving for budget issues
- Explore the option of payment over time and tying payment to outcomes

Edmund Pezalla, CEO & Founder of **Enlightenment Bioconsult, LLC**

2.00 – 3.00pm Afternoon Refreshments & Debrief

3.00 – 5.00pm Engineering T Cells for Solid Tumor Applications, The End of The Beginning

- History and perspective of engineered T cells in solid tumor applications
- Do checkpoint antibody results point to paths forward?
- Overview of the tumor microenvironment (TME)
- What technologies can enhance engineered T cell function in the TME?

Rick Morgan, Vice President of Immunotherapy, **bluebird bio**

3.00 – 5.00pm The Challenges of Correlative and Release Test Assays for Evaluating Gene Edited Human Cell Products

- This workshop will discuss the development and validation of new correlative and release test assays to evaluate efficiency of transduction, gene editing, incidence of off-target cleavage, translocation events and other aspects of gene edited human cells:
- The FDA requires additional evaluations of such gene edited and engineered cells prior to, and post infusion
 - Gene editing techniques such as CRISPR/Cas9 hold potential for augmentation of CAR-T and TCR engineered cell products to be used in human clinical trials

Simon Lacey, Director Translational and Correlative Studies Laboratory, Center for Cellular Immunotherapies, **UPenn**

3.00 – 5.00pm Confronting Analytical Challenges of Chimeric Antigen Receptor T Cell

- CAR-T presents unique challenges for analytical development due to its complex mechanism of actions, inherent heterogeneity of the starting material, lack of appropriate reference material, and the limited lot size and testing material
- This workshop will use Liso-Cel as a case study to illustrate how an integrated bioanalytical and analytical development strategy enables product characterization for a late phase CAR-T program

Eileen Higham, Head of Analytical and Process Development, **Juno Therapeutics**

3.00 – 5.00pm Delivering Next Generation CAR-T Therapies

- Exploration of next generation CAR-T process and analytical technologies
- What systems are essential to meet the increased global demand, while reducing COGs?
- Why are data management systems and bioinformatics so essential?

Rodney Rietze, Enabling Technology and Strategic Development, **Novartis**

3.00 – 5.00pm Investigating the Regulatory Landscape of CAR-T Therapy

- Understand the availability of regulatory incentives for the development of CAR-T therapies
- Guidance to create a tailored integrated development plan
- Explore a risk-based approach for CAR-T regulations

Gopalan Narayanan, Vice President, **Disruptive Biologics**

5.00pm Evening Refreshments & Debrief

Summit Day 1 | Wednesday September 5th

7.00 Breakfast & Registration

8.00 Welcoming Remarks



Shaksita Desai
Brand Director, CAR-TCR Series
Hanson Wade

8.15 Opening Ceremony:

Join one of the field's leading minds as we officially open the CAR-TCR Summit. Carl June shares his experiences and expertise pioneering one of the most revolutionary cancer therapeutics in decades.



Carl June
University of Pennsylvania

8.45



9.15 Late Breaking Abstracts

Key companies will present new data for the first time at the CAR-TCR Summit. Be sure not to miss the session of the year and be the first to hear these new clinical trial read outs.



Cheng Liu
CEO
Eureka Therapeutics



Devon Shedlock
VP, Preclinical Development
Poseida Therapeutics

10.15 Speed Networking

10.45 Refreshments

CAR-TCR Discovery Track:

11.15 Novel and Next Generation Targets and Approaches for Solid Tumors
Steffen Walter, Co-Founder & CSO, **Immatics Biotechnologies**

CAR-TCR Translation Track:

11.15 Phase 3 Development of tabcel™, An Off-the-Shelf, Allogeneic T-Cell Immunotherapy for Epstein-Barr Virus Associated Lymphoma
Chris Haqq, EVP, R&D & CSO, **Atara Biotherapeutics**

CAR-TCR Manufacturing Track:

Chairman: Robert Preti, CEO & President, **Hitachi Chemical Advanced Therapeutic Solutions**

11.15 Manufacturing CART Cells to Treat Solid Tumor Indications
Zonghai Li, CEO, **Innovative Cellular Therapeutics**

CAR-TCR Transport, Logistics & Supply Chain Track:

11.15 Optimizing Strategic Sourcing and CAR-T Supply Chain for Global Therapeutic Delivery
George O'Sullivan, Executive Director, Global CAR-T Supply Chain, **Celgene**

CAR-TCR Commercialization Track

11.15 Valuing CAR-T Therapy: Summarizing the ICER Experience
Jeffrey Tice, Professor of Medicine, Division of General Internal Medicine, **University of California San Francisco**

11.25 Affinity Tuned CAR-T Cells for Differential Targeting of Tumor-Associated Antigens

Eric Von Hofe, President, **Afflymune Therapeutics**

11.25 Precision Immunotherapy: CAR T-Cell Therapy for Multiple Myeloma

Yuan Xu, CEO, **Legend Biotech**

11.25 Manufacturing Innovations: Building a Bioprocessing Toolbox

Jim Faulkner, SVP, Head, Product Delivery, **Autolus**

11.25 Lessons Learned from Approved Products: Kymriah Leveraging Integrated Technologies to Orchestrate and Support Commercial Activities

Samuele Butera, Global Head, Cell & Gene Therapies Business Leader, **Novartis**

11.15 Optimizing the Cell Therapy Ecosystem for Effective Delivery of Therapies to Patients in Need

Axel Hoos, SVP, TA, **Head Oncology R&D, GSK**

12.00 Novel CAR-T Cells Against Solid and Hematological Cancers

Vita Golubovskaya, Director, R&D, BD, **Promab Biotechnologies**

12.00 Regulated, Multi-Dimensional CAR-T Therapy May Breakthrough Solid Tumors

David Spencer, CTO, **Bellicum Pharmaceutical**

12.00 Innovative Material Options to Fuel Advances in CAR-T Therapies via Automation

Claudia Zylberberg, CEO, **Akron Biotech**

12.00 Overcoming the Complexities of the Personalized Medicine Supply Chain

Scott Ohanesian, SVP, Commercial Operations, Clinical Trial Logistics, QuickSTAT, **A Quick Company**

12.00 Payer Perspectives of Pricing and Reimbursement of CAR-T Therapies Reimbursement and Coding Systems Required for CAR-T Therapy Delivery

12.30 Lunch

12.30 Private Lunch Hosted by  Attendance by Invitation Only

2.00

biotechne

2.00 Biomarker Development to Measure Response to Therapies in Patients

John Rossi, Director, Translational Sciences, **Kite Pharma, a Gilead Company**

2.00 Automation and Decentralization of CAR-T Cell Manufacture

Boro Dropulic, CSO & General Manager, Lentigen Technology, **A Miltenyi Biotec Company**

2.00 Chain of Compliance: The Standardization of Precision Medicine Logistics

Mark Sawicki, Chief Commercial Officer, **Cryoport**

2.00 Partnering and Collaboration from Discovery through Commercialization: Who Are the Stakeholders and How to Ensure You Get the Best from Them

2.35 Roundtable Discussion Session:

- Overcoming the Tumor Microenvironment through Cytokine Stimulation and Modulation
- Understanding the Metabolic Conditions of Tumors to Enhance Therapy Efficacy
- Overcoming Toxicities in CAR-T Therapies to Prevent Adverse Side Effects

2.35 Roundtable Discussion Session:

- Combination Therapy Strategy for Product Optimization
- Methods to Improve In Vivo Expansion and Track Cells In Vivo to Identify Persistence
- Development of Long Term Follow-up and Correlative Studies to Inform Next Generation Drug Development

2.35 Roundtable Discussion Session:

- Overcoming the Viral Vector Engineering Bottleneck
- Developments in Viral Vector Manipulation for In Vivo Gene Editing
- Automation of CAR-T Therapies to Create a Robust Closed Manufacturing System

2.35 Roundtable Discussion Session:

- Developing the Appropriate Infrastructure for Global Delivery of CAR-T Therapies
- Ensuring a Streamlined Transport and Logistics Chain from Receiving Patient Material Delivery of Therapy
- Labeling and Chain of Custody Requirements for CAR-TCR Therapy Delivery

2.35 Roundtable Discussion Session:

- Pricing Models for Novel Engineered Cell Therapies
- Market Access and Health Economics Challenges of Engineered Cell Therapies on Market
- Ethical Considerations of Pricing and Reimbursement of Curative Therapies

3.35 	3.35 	3.35 Real-Time Monitoring of CAR-T-Mediated Potency Assays and Its Modulation by Checkpoint Inhibitors Yama Abassi, VP, Global Strategic Business Development, ACEA Biosciences	3.35 Techniques for Navigating the Cell Therapy Supply Chain: When Exceptions are the Norm Jamie Margolis, Director, Product Development Operation, Be The Match Biotherapies	3.35 Education Protocols and Practices for HealthCare Professionals Delivering CAR-TCR Therapies
4.10 PANEL: How to Make CAR/TCR Therapies Work Beyond the CD19/ALL Paradigm? Koji Tamada, CSMO, Noile-Immune Biotech Eric Van Hofe, President, Afflymune Therapeutics for Glioblastoma Steffen Walter, Co-Founder & CSO, Immatics Biotechnologies	4.10 PANEL: Methods to Predict CAR-T Therapy Patient Response to Inform Patient Selection and Trial Design Sean Mackay, CEO, Isoplexis John Rossi, Director, Translational Sciences, Kite Pharma, a Gilead Company	4.10 PANEL: How can we Create an Allogeneic, Virus Free Manufacturing Process? David Sourdive, EVP, Technical Operations, Collectis Mike Stella, Chief Business Officer and Director, Cognate Bioservices	4.10 PANEL: How can we Improve logistics and case management for improved distribution of CAR-TCR therapies Rona Singer Weinberg, Director, Cellular Therapy Laboratory Director, MPD Laboratory, New York Blood Center, Blood Centers of America	4.10 PANEL: How can we Use Next Generation Analytics and Data Science Technologies Needed to Inform CAR-T Commercialization

5.10 The Continuum of CAR-T Development: What Are the Needs at Each Stage of Development

TERUMOBCT

5.40 Drinks Reception

Extremely well organized. Perfect size with focus that enabled maximal interaction. Loved the speed dating concept

Past Attendee, Director of Pfizer



Summit Day 2 | Thursday September 6th

7.00 Breakfast & Registration

8.00 Opening Remarks & Day 1 Summary

8.30 Next Generation CAR-TCR Therapies: Executive Leaders' Fireside Chat

After the first of the CD19 candidates due to hit the market this year, what are the next steps, where do we go now? Take this opportunity to ask the leaders what their future plans are and what we can expect from the CAR-TCR space over the next few years.



James Noble
CEO
Adaptimmune



David Chang
CEO
Allogene Therapeutics



Philip Gregory
CSO
bluebird bio



André Chouluka
CEO
Collectis



Usman Azam
President & CEO
Tmunity

9.30 Smart, Closed & Connected Solutions for Cell Therapy Production



Philip Vanek
GM, Cell Therapy Growth Strategy
GE Healthcare

10.00 Driving Adoption of Your CAR-T Therapy with a Proven Logistics and Access Strategy



Jennifer Fillman
Vice President & General Manager, Specialty Services
Cardinal Health Specialty Solutions

11.00 Innovation Hub & Tech Slam

11.00 Refreshments & Networking

CAR-TCR Discovery Track:

12.00 **PANEL: What are the Pros and Cons of the Various Gene Editing Technologies for CAR-TCR Therapies?**

Andre Chouluka, CEO, **Collectis**
Bing Wang, CEO, **Refuge Biotechnologies**
Gary Lee, VP, Cell Therapy, **Sangamo Biosciences**

CAR-TCR Translation Track:

12.00 **PANEL: Creating Novel Strategies to Overcome the Inhibitory Tumor Microenvironment**

Thomas Andresen, Co-founder and CSO, **Torque Therapeutics**

CAR-TCR Manufacturing Track:

12.00 **PANEL: How Much Automation is Too Much Too Soon Given the Evolving Nature of the Technology?**

Peter Olagunju, VP, Technical Operations, **bluebird bio**
Jim Faulkner, SVP, Head, Product Delivery, **Autolus**

CAR-TCR Transport, Logistics & Supply Chain Track:

12.00 **PANEL: What Technologies and Innovations Need to be Explored for Successfully Integrated Logistics for CAR-TCR Therapy Delivery?**

George O'Sullivan, Executive Director, Global CAR-T Supply Chain, **Celgene**

CAR-TCR Commercialization Track

12.00 **PANEL: How Can We Ensure Accessibility and Affordability OF CAR-TCR Therapies**

Jeffrey Tice, Professor of Medicine, Division of General Internal Medicine, **University of California, San Francisco**
Axel Hoos, SVP, TA, Head Oncology, R&D, **GSK**
Andrew Brown, Jr., Director, Diversity and Equity Advocacy, ICAN, **International Cancer Advocacy Network**

1.00 CAR-T Cell Mechanistic Control in vivo for Improved Efficacy: Utilizing Switch Mechanisms

Andy Phillips, CEO, **C4 Therapeutics**

1.00 GM-CSF Neutralization as a Strategy to Optimize CAR-T Cell Therapy and Mitigate Induced Toxicities

Saad Kenderian, Director, T cell Engineering Program, **Mayo Clinic**

1.00 Building CAR-T Manufacturing Procedures in Compliance with Domestic and Foreign Regulatory Guidelines

Jie Jia, Vice President, **CARsgen Therapeutics**

1.00 Creating Efficient Commercial Cold Chain Supply for Effective Storage and Transport

12.35 Patient Advocacy: Ensuring Patients Have Access to Life-Changing Therapies

Andrew Brown, Jr, Director, Diversity and Equity Advocacy, **ICAN, International Cancer Advocacy Network**

1.30 Lunch & Networking

1.30 Private Lunch Hosted by  BD Attendance by Invitation Only

3.00 Optimizing Lentiviral Production in Suspension Culture with Gibco LV-MAX Lentiviral Production System
Speaker TBC, ThermoFisher Scientific

3.00 Acoustic Cell Processing - An Innovation in Cell Therapy

Richard Grant, Chief Product Officer, **FloDesign Sonics**

3.00 On-Demand and On-Site Delivery of Customizable Multiparametric Cell and Immunoassays with Automated Data Analytics on the Processing Floor

Bala Manian, Executive Chairman, **LeukoDx**

3.00 Enabling Commercialization Using Cloud-Deployed Technology

Heidi Hagen, Co-founder & CSO, **Vineti**

3.00 Overcoming the Technical Challenges Involved with Delivering Complex CAR-T and TCR Therapies to Patients

Matthew Robson, Global Head Medical Affairs, Cell & Gene Therapies Unit, **Novartis**

3.35 Conditional and Multiplexed Gene Expression Programming in Cell Therapies Utilizing CRISPR i/a

Bing Wang, CEO, **Refuge Biotechnologies**

3.35 Migration, Homing and Trafficking: Getting the CAR-T Cells Where They Need to be

Peter Emtage, Global Head, Cell Therapy, **Kite Pharma, a Gilead Company**

3.35 The Current State of CAR-T Allogeneic Manufacturing Processes

Yajin Ni, Director, CAR-T Manufacturing Process Development, **Pfizer**

3.35 Viral Vector Engineering and Analytics

Gillian Payne, Director, Vector Analytics, **bluebird bio**

3.35 How to Get a Site Ready and Approved for CAR-TCR Therapy Treatment: Developing and Setting up The Healthcare Facilities to Deliver CAR-TCR Therapies

Joseph McGuirk, Professor of Medicine, **The University of Kansas Health System**

4.10 Highly Efficient Dual Knock-Out of Endogenous T-Cell Receptor and HLA Class I using Zinc Finger Nucleases for Allogeneic T Cell Therapy

Gary Lee, Vice President, Cell Therapy, **Sangamo Biosciences**

4.10 Enhancing T cell Expansion and Survival to Induce Long-Term Memory Responses

Koji Tamada, CSMO, **Noile Immune Biotech**

4.10 Creation of an Off-the-Shelf TCR-less CAR T cell with Capacity to Overcome Antigen Escape

Bob Valamehr, VP, Cancer Immunotherapy, **Fate Therapeutics**

4.10 Overcoming the Viral Vector Bottleneck to Improve Turn Around Time and Efficiency of Therapy Delivery

4.10 Partnering and Collaboration from Discovery through Commercialization

4.45 Putting Patients First: How Has the Face of Cancer Therapy Changed

5.15 Closing Ceremony Panel Discussion: Lessons Learnt from the Leaders



Samuele Butera
Global Cell & Gene Therapies Business Leader
Novartis



Carl June
Professor & Director Translational Research, Abramson Cancer Center
University of Pennsylvania

6.15 Chairman's Closing Remarks

6.30 Close of Summit & Goodbye



Shaksita Desai
Brand Director, CAR-TCR Series
Hanson Wade

Focus Day Agendas | Friday September 7th

Agenda 1	Agenda 2
Overcoming CAR-T Toxicity in Solid Tumors	Alternative CAR Strategies
9.00 Overcoming Manufacturing Challenges in Solid Tumors • Explore manufacturing strategies to create a GMP-in-a-box process • Methods to reduce footprint and increase throughput • Discuss an easily transferrable process that would reduce variation between centers and make transfers seamless Isabelle Riviera, Director, Cell Therapy & Cell Engineering Facility, Memorial Sloan Kettering Cancer Center	9.00 Developing Gamma-Delta CAR-T to Treat Cancer and Viral Disease • Generating a tox-free CAR-T • Pharmaceuticalization of gamma-delta T cell therapies • Sustainable business models Michael Leek, Chief Executive Officer, TC BioPharm
9.30 Manufacturing Spear T-Cells for Autologous Therapy of Solid Tumors • SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cells recognize HLA-restricted tumor antigens, and show clinical promise in exploratory trials • Reliable manufacturing is key for early phase trials, and requires specialized supply chain, process development, and analytic strategies • Process optimization can be explored in early phase trials, while reduced analytic testing and decreased process flexibility is required for mature products. Mark Dudley, Senior Vice President of Bioprocessing, Adaptimmune	9.30 Future of Virus Specific T Cells in Oncology • Redirecting antiviral immunity • The VST as a platform for solid tumor cell therapy • Clinical application of VST technology • Rational combination therapy for next generation immunoncology John Connolly, Chief Scientific Officer, Tessa Therapeutics
10.00 Panel Discussion: Strategies to Increase Efficacy of CAR-T in Solid Tumors • Lack of unique tumor-associated antigen in most cancers • Inefficient trafficking of CAR-T cells to tumor sites • Presence of immunosuppressive molecules and cells • Metabolically hostile tumor microenvironment Miguel Forte, Chief Executive Officer, Zelluna Immunotherapy Mario Marcondes, Medical Director, Clinical Development, Nektar Therapeutics Charles Sentman, Professor of Microbiology and Immunology, Dartmouth Geisel School of Medicine	10.00 Panel discussion: Building Sustaining Business Models for CAR Therapies • Explore different business strategies to reduce cost of goods • Identify different models to make CAR therapies more commercially viable • Discuss the opportunities in allogeneic CAR-T therapies Michael Leek, Chief Executive Officer, TC BioPharm Jim Beitel, SVP, Corporate Development, Fate Therapeutics Robert Hofmeister, Chief Scientific Officer, TCR2 Therapeutics
11.00 Morning Refreshments & Networking	

Focus Day Agendas

12.00 CAR T Cell Therapy for Glioblastoma: Progress, Promises and Challenges

- Optimizing CAR T Cell delivery into the brain
- Identifying barriers to CAR T cell responses in malignant brain tumors
- Future directions in enhancing CAR T cell therapy for glioblastoma

Behnam Badie, Professor and Chief, Division of Neurosurgery & Director, Brain Tumor Program, **City of Hope Medical Center**

12.30 Claudin18.2-Targeted Car-T for the Treatment of Patients with Pancreatic Cancer or Gastric Cancer

- Development of Claudin18.2-targeted CAR-T cells
- The safety profile of claudin18.2 -targeted CAR-T cells
- Efficacy of claudin18.2-targeted CAR-T cells

Zonghai Li, Founder, CEO and CSO, **CARSGen Therapeutics**

1.00 Overcoming Safety Challenges of Genetically Engineered T-Cell Therapy for the Treatment of Cancer

- Safety challenges such as CRS and neurotoxicity are widely observed in T-cell therapy treatments, Eureka developed its proprietary ARTEMIS™ platform to tackle the problem
- In-vitro and mouse in-vivo data has shown robust and specific killing activity of our leading programs: ET190L1- ARTEMIS™ and ET1402L1- ARTEMIS™
- Clinical experience of ARTEMIS™ platform-based T-cell therapy

Bijan Nejadnik, CMO, **Eureka Therapeutics**

12.00 Use of NKT Cells for The Development of off-the-shelf CAR Products Without The Need for Gene Editing

- Explore the use of NKT cells in allogeneic settings without the need for gene editing due to their invariant, targeting pathogen-specific glycolipids that are not found on human cells and therefore do not cause graft versus host disease
- Discuss the development of multiple products based on the CAR-NKT platform against indications of high unmet medical need, in very close partnership with the Baylor College of Medicine
- Explore the enhanced persistence and activity in solid tumors of Cell Medica's products which are engineered to secrete cytokines

Stefanos Theoharis, SVP, Partnering and Corporate Development, **Cell Medica**

12.30 Developing Novel CAR-Macrophage Therapies for Solid Tumors

- Macrophage biology is ideally suited for solid tumors
- Explore the unique challenges in developing CAR-Macrophages to enhance efficacy in solid tumors
- Leveraging CAR-T production insights for supply chain

Steven Kelly, President and CEO, **CARMA Therapeutics**

1.00 CAR-T cells and Combination Therapies: The Next Chapter of the Immuno-Oncology Revolution

This talk will initially review general combination strategies for CAR-T therapies and will subsequently focus on Mustang Bio's combination strategy for solid tumors

- The impressive results demonstrated by CAR-T therapies are driving interest in immunotherapy combinations that have a synergistic mechanism of action
- Combination strategies are a key area of clinical research and may unlock the potential of immune-oncology therapies by overcoming multiple mechanisms of immune evasion and targeting non-redundant pathways

Sadik Kassim, Chief Scientific Officer, **Mustang Bio**

1.30 Lunch & Networking

Focus Day Agendas

2.30 Deep Primed™ Immunotherapy: Controlling The Tumor Microenvironment in T Cell Therapy

- Torque is developing Deep Primed™ cell therapies that direct and evoke immune responses in the tumor and immune microenvironment
- The Torque platform makes it possible to anchor powerful stimulatory cytokines, antibodies, and small molecules directly to immune cells to direct their activity and increase their efficacy and durability in the “hostile” tumor microenvironment, while controlling systemic exposure
- Torque's lead product candidate is Deep IL-15, which is entering clinical development for hematologic and solid tumors

Thomas Andresen, Co-founder and CSO, **Torque Therapeutics**

3.00 CAR19 T Cells Carrying Multi-Antigen Targeting Payloads: Tackling Persistence and Tumor Antigen Heterogeneity for the Treatment of Diverse Tumors

- IMPACT™ technology enables robust and modular antigen targeting using a single CAR
- Multiple antigens are attacked simultaneously, with low pM activity
- Technology addresses critical issues of antigen loss and antigen heterogeneity

Paul Rennert, President & CSO, **Aleta Biotherapeutics**

2.30 Accessories for Your CAR: Combining Cells With Drug Therapy to Improve Outcomes

- Review anticipated outcomes with conventional CAR T cell therapy (primarily CLL/NHL)
- Rationale for combination therapy
- Discuss results of CAR T cells plus drugs therapies
 - ibrutinib
 - check point inhibitors
- Discuss concerns regarding combinations (toxicity, GVHD, cost) and scheduling (when to start, duration of therapy, when to stop?)

David Porter, Director of Cell Therapy and Transplant, **University of Pennsylvania**

3.00 A Novel Approach Near Term to Optimize Current and Future CAR-T

- Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a key driver in CAR-T-induced toxicities, particularly neurotoxicity, which remain a barrier to expanded use
- Studying lenzilumab, a novel monoclonal antibody that neutralizes circulating GM-CSF, to optimize current CAR-T by preventing or minimizing serious side effects and potentially boosting efficacy
- Establishing this mechanism also has the potential to expand CAR-T use, including aiding expansion into solid tumors and synergies with checkpoint inhibitors

Cameron Durrant, Chairman and Chief Executive Officer, **Humanigen, Inc.**

3.30 Close of Focus Day

Build Your Own CAR-TCR Experience

Speed Networking



Your opportunity to make valuable new contacts in a short space of time

This session is fast paced aiming to provide brief introductions to as many participants at the CAR-TCR Summit as early on in the meeting as possible. The renowned speed networking session will be one of the most valuable hours you spend at this summit.

Tech Slam & Innovation Hub



Want a quick snapshot of new technological innovations being developed?

This session alongside the hub provides you with an opportunity to discover the latest technological advances that are being made in this space to enhance the success and commercial delivery of CAR-TCR therapies.

5 Track Summit



An end-to-end focus means looking at the key aspects of development

We have separated the key challenges into 5 key areas of development - discovery, translation, manufacturing, transport, logistics & supply chain, and commercialization. Follow one track throughout the full conference or switch it up and jump between sessions you're interested in, tailor your agenda to your needs.

Poster Session



Share your work with the pioneers of CAR-TCR therapeutic development

Bring a poster and gain feedback on your latest research with this expert community. Growing through popular demand, this exciting session brings you hot new data highlighting innovating research.



Deep Dive Sessions



30 minutes can only provide you with so much detail on the topic at hand

Deep Dive Sessions allow you to spend 2 hours with an expert to really get to grips with a specific topic area, learn from the leaders individual experience and expertise as they share case studies and combine this with the shared expertise and experience in the audience. Interact, discuss and debate to get your questions answered so you have real tangible actions to take back to the office with you.



Focus Day Agendas



You told us you wanted to hear more about CAR-Ts in solid tumors and alternative CAR therapies such as CAR-NKs

So instead of giving you less of something else we created a two track dedicated post day bringing you end-to-end content focused solely on the progress being made in solid tumors and the progress being made utilising alternative CAR strategies. The same as the main day, follow one track throughout the day or jump sessions. Build value where you want.



Partnering with the CAR-TCR Summit

The *CAR-TCR Summit* is **your fastest route** to organizations pioneering CAR-T and TCR therapy development. This year over 700 stakeholders and influencers across the discovery through to commercialization will attend the *CAR-TCR Summit*.

This meeting is **your opportunity to influence industry** thinking as the landscape rapidly grows and changes.

Join us as a partner to ensure you are front of mind as decisions of strategy are being made for the next 12 months and beyond.

At the *CAR-TCR Summit* we understand that when it comes to meaningful partnership opportunities, there is no one size fits all approach. Your business has specific goals and expertise to showcase, so when you partner with the *CAR-TCR Summit*, we build you a bespoke partnership **tailored to meet your needs**.


If you have a technology or service that can benefit the CAR-TCR community we'd love to work with you. Contact Jonathan or Philip on the details below to discuss your objectives.

Contact us to find out more


Contact: Philip Johnson & Jonathan Kilby-Phillips
Commercial Managers, Cell & Viral Immunotherapy
Tel: +1 212 537 5898
Email: sponsor@hansonwade.com

Who You'll Meet

Attendance by Geo



Attendance by Company Type



700+
ATTENDEES



300+
COMPANIES AND
INSTITUTES



63%
DIRECTOR LEVEL &
ABOVE



70%
PHARMACEUTICAL
& BIOTECH DRUG
DEVELOPERS

Very targeted meeting filled with KOLs and industry leaders in this exciting field. Meeting organized and run better than any other conference I have attended

IntelliCyt

Great opportunity where I made over 10 key contacts that would not have been made otherwise. Progressed 1 key collaboration already!

ACEA Biosciences

CAR-TCR Summit Partners

Lead Partner



Expertise Partner



Program Partners



CAR-TCR Summit Partners

Hosting Partners



Exhibitors & Partners



Venue

Seaport Hotel & World Trade Center
One Seaport Lane
Boston, MA
02210
USA

Located in the popular Seaport District, the Seaport Hotel is adjacent to downtown Boston, perfectly located for both business and pleasure. It is just ten minutes from Boston Logan International Airport with easy connections by public transport or a quick taxi ride. More than 100 popular bars, restaurants, museums, parks and Boston's famous Harborwalk are all just outside. We have a preferential rate available at the Seaport Hotel & World Trade Center exclusively for attendees of the 4th CAR-TCR Summit 2018.

Take advantage of the preferential rate



Please note: Overnight accommodation and travel are not included in the registration fee.

Pricing & Discounts

CAR-T and TCR Therapy Developers*	Book before 1st June and save up to \$450	Final Online Price
Gold package: Summit Days + Deep Dive Discussion Day AND Focus Day	\$4,547	\$4,997
Silver package: Summit Days + Deep Dive Discussion Day OR Focus Day	\$3,548	\$3,998
Bronze package: Summit Days Only	\$2,349	\$2,799

Academics	Book before 1st June and save up to \$450	Final Online Price
Gold package: Summit Days + Deep Dive Discussion Day AND Focus Day	\$3,547	\$3,997
Silver package: Summit Days + Deep Dive Discussion Day OR Focus Day	\$2,548	\$2,998
Bronze package: Summit Days Only	\$1,349	\$1,799

Standard	Book before 1st June and save up to \$450	Final Online Price
Gold package: Summit Days + Deep Dive Discussion Day AND Focus Day	\$5,547	\$5,997
Silver package: Summit Days + Deep Dive Discussion Day OR Focus Day	\$4,548	\$4,998
Bronze package: Summit Days Only	\$3,349	\$3,799

* Must be from a biotech or pharma company that is currently and publicly developing an in-house CAR-T or TCR therapy to be eligible for this price

Team Discounts*

- **10% discount** – 3 delegates
- **15% discount** – 5 delegates
- **20% discount** – 10 or more delegates

Please note that discounts are only valid when three or more delegates from one company book and pay at the same time.

TERMS & CONDITIONS

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Hanson Wade reserves the right to postpone or cancel an event, to change the location or alter the advertised speakers. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Database Manager, Hanson Wade, Suite A, 6 Honduras Street, London EC1Y 0TH

Register

www.car-tcr-summit.com/register-2018

Tel: +1 212 537 5898

Email: register@hansonwade.com

Mail: Hanson Wade, 4th Floor, 52 Grosvenor Gardens, London, SW1W 0AU